Viewing Study NCT07030569

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:59 PM
Ignite Modification Date: 2026-05-27 @ 1:49 PM
Study NCT ID: NCT07030569
Status: RECRUITING
Last Update Posted: 2025-06-22
First Post: 2025-01-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Radiomic View
None Radiomics View
None Breast Cancer Metastatic View
None Breast Cancer Stage IV View
None Breast Carcinoma View
None Breast Neoplasms View
None Breast Cancer View
None Breast Cancer With Bone Metastasis View
None Breast Cancer With Metastatic Bone Disease View
None Trastuzumab View
None HER2 View
None HER2 + Breast Cancer View
None HER2 Positive Breast Carcinoma View
None HER2-positive Breast Cancer View
None Her2/Neu Positive Advanced Solid Tumors View
None HER2/Neu-positive Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Radiomics View
None HER2 expression View
None Trastuzumab Deruxtecan View
None Pathomics View
None HER2 heterogeneity View